AC Immune SA (ACIU) Stock Price

ACIUStock
$2.92+33.02%52W
Market Cap$290.33M
P/E
PEG Ratio
Div yield
Beta1.55

ACIU Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-2.09%
Price vs S&P 500 (4W)20.22%
VGM Score48.46

ACIU Earnings Surprise History

Q2 25-0.26est. -0.20
Q3 25-0.20est. -0.22
Q4 25-0.17est. -0.21
Q1 26-0.19est. -0.17
Q2 260.02est. -0.14

ACIU Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.40
4.40
4.40
4.40

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
ACIUAC Immune SA
CDB$2.92
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company focused on neurodegenerative diseases caused by protein misfolding. The company uses proprietary technology platforms to develop small molecules, antibodies, and vaccines for both therapeutic and diagnostic applications. Its pipeline includes clinical-stage candidates such as Crenezumab and Semorinemab.